Compare
Monte Rosa Therapeutics, Inc. vs Atara Biotherapeutics, Inc. vs Agenus Inc vs ImmunityBio, Inc.
| Latest fiscal year | Monte Rosa Therapeutics, Inc. GLUE | Atara Biotherapeutics, Inc. ATRA | Agenus Inc AGEN | ImmunityBio, Inc. IBRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $123.67M | $120.77M | $114.20M | $113.29M |
| Revenue growth (YoY) | +63.5% | -6.3% | +10.4% | +668.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -43.8% | 29.7% | -17.7% | -226.0% |
| Net margin | -31.2% | 27.1% | -2.7% | -310.2% |
| Net income | -$38.63M | $32.69M | -$3.08M | -$351.40M |
| EPS (Diluted) | n/a | $2.57 | $0.00 | -$0.38 |
| Operating cash flow | -$22.80M | -$50.94M | -$77.19M | -$304.94M |
| Free cash flow | -$27.50M | -$50.94M | -$77.20M | -$308.78M |
| Cash & equivalents | $129.88M | $8.48M | $3.00M | $88.33M |
| Total assets | $448.66M | $20.23M | $226.80M | $501.90M |
| Total liabilities | $215.60M | $58.74M | n/a | $1.00B |
| Shareholders' equity | $233.06M | -$38.50M | -$271.11M | -$500.47M |
| Return on year-end equity | -16.6% | n/a | n/a | n/a |
| Shares outstanding | 65.54M | 7.32M | 35.32M | 1.01B |
Revenue, most recent five fiscal years
| Fiscal year | Monte Rosa Therapeutics, Inc. | Atara Biotherapeutics, Inc. | Agenus Inc | ImmunityBio, Inc. |
|---|---|---|---|---|
| Latest | $123.67M Ended 2025-12-31 | $120.77M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $113.29M Ended 2025-12-31 |
| 1 year earlier | $75.62M Ended 2024-12-31 | $128.94M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $14.74M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $8.57M Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $622.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $63.57M Ended 2022-12-31 | $98.02M Ended 2022-12-31 | $240.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $295.67M Ended 2021-12-31 | $934.0K Ended 2021-12-31 |